- Akebia Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Akebia Therapeutics Inc Earnings Call TranscriptNov 08, 2023$0.96 (-11.93%)Earnings
- Q2 2023 Akebia Therapeutics Inc Earnings Call TranscriptAug 25, 2023$1.15 (-8.00%)Earnings
- Akebia Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Akebia Therapeutics Inc To Discuss The Response To The FDRR TranscriptMay 30, 2023
- Q1 2023 Akebia Therapeutics Inc Earnings Call TranscriptMay 08, 2023$1.06 (-2.75%)Earnings
- Akebia Therapeutics Inc to Host Stockholder Information Session TranscriptApr 21, 2023
- Q4 2022 Akebia Therapeutics Inc Earnings Call TranscriptMar 09, 2023$0.8007 (-22.26%)Earnings
- Q3 2022 Akebia Therapeutics Inc Earnings Call TranscriptNov 03, 2022$0.2851 (+7.34%)Earnings
- Q2 2022 Akebia Therapeutics Inc Earnings Call TranscriptAug 04, 2022$0.41 (+4.99%)Earnings
- Q1 2022 Akebia Therapeutics Inc Earnings Call TranscriptMay 09, 2022$0.3454 (-10.26%)Earnings
- Akebia Therapeutics Inc Corporate Call TranscriptMar 30, 2022
- Akebia Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- Q3 2021 Akebia Therapeutics Inc Earnings Call TranscriptNov 09, 2021$2.86 (-0.35%)Earnings
- Akebia Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) TranscriptSep 27, 2021
- Akebia Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Akebia Therapeutics Inc Earnings Call TranscriptAug 05, 2021$2.87 (+15.73%)Earnings
- Akebia Therapeutics Inc Annual Shareholders Meeting TranscriptJun 02, 2021
- Q1 2021 Akebia Therapeutics Inc Earnings Call TranscriptMay 10, 2021$2.9 (-7.05%)Earnings
- Q4 2020 Akebia Therapeutics Inc Earnings Call TranscriptFeb 25, 2021$3.47 (-18.93%)Earnings
- Akebia Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Q3 2020 Akebia Therapeutics Inc Earnings Call TranscriptNov 05, 2020$2.49 (-3.11%)Earnings
- Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined TranscriptOct 23, 2020
- Akebia Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2020
- Akebia Therapeutics Inc Conference Call and Live Webcast to Discuss the PRO(2)TECT Data TranscriptSep 03, 2020
- Akebia Therapeutics Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 02, 2020
- Q1 2020 Akebia Therapeutics Inc Earnings Call TranscriptMay 05, 2020$11.95 (+37.99%)Earnings
- Q4 2019 Akebia Therapeutics Inc Earnings Call TranscriptMar 10, 2020$7.43 (-7.70%)Earnings
- Akebia Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Q3 2019 Akebia Therapeutics Inc Earnings Call TranscriptNov 12, 2019$3.33 (-9.02%)Earnings
- Akebia Therapeutics Inc at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Q2 2019 Akebia Therapeutics Inc Earnings Call TranscriptAug 08, 2019$4.17 (+13.93%)Earnings
- Q1 2019 Akebia Therapeutics Inc Earnings Call TranscriptMay 09, 2019$5.92 (+0.51%)Earnings
- Q4 2018 Akebia Therapeutics Inc Earnings Call TranscriptMar 18, 2019Earnings
Akebia Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript
(inaudible) registration desk. So I'd like to welcome to the stage with me from Akebia Therapeutics, CEO, John Butler. I'm one of the analysts here, David Lebowitz. Akebia's a fully integrated nephrology company, which has undergone some change in the last year, certainly with an integration. I guess before we really get started, could you just give a top level overview of the company and where it's come from and where it's going?
Sure, David. First, thanks so much for having us here today. As you said, Akebia is a fully integrated biopharma company that is focused on delivering innovative therapies for patients with kidney disease. And we have a commercial product now in Auryxia with 2 indications, hyperphosphatemia and iron deficiency anemia. And then we have our Phase III product, vadadustat, which is a hypoxia-inducible factor prolyl hydroxylase inhibitor, that's in development for treating the anemia of chronic kidney
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)